Highlighting 'Pay For Delay' Concerns
These reports shine a spotlight on the interplay between authorized generics and pharmaceutical patent settlements, and indicate strong FTC opposition to a practice that has never been found unlawful.
Report on Authorized Generics
On Aug. 31, 2011, the FTC issued its...
To view the full article, register now.